EdgarLookup

Perspective Therapeutics, Inc. — Quarterly Financials

Quarterly figures from SEC EDGAR XBRL filings (10-Q)

These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Perspective Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.

Overview All Filings Annual Quarterly Insiders

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2023 Sep 30, 2023 $2.19M Nov 14, 2023
Q2 2023 Jun 30, 2023 $2.09M Aug 11, 2023
Q1 2023 Mar 31, 2023 $2.06M May 15, 2023
Q3 2023 Sep 30, 2022 $1.72M Nov 14, 2023
Q2 2023 Jun 30, 2022 $2.51M Aug 11, 2023
Q1 2023 Mar 31, 2022 $2.91M May 15, 2023
Q2 2019 Dec 31, 2018 $1.90M Feb 13, 2019
Q1 2019 Sep 30, 2018 $1.56M Nov 9, 2018
Q3 2018 Mar 31, 2018 $1.57M May 4, 2018
Q2 2019 Dec 31, 2017 $1.54M Feb 13, 2019
Q1 2019 Sep 30, 2017 $1.21M Nov 9, 2018
Q3 2018 Mar 31, 2017 $1.28M May 4, 2018

Net Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($25.97M) Nov 10, 2025
Q3 2025 Jun 30, 2025 ($21.49M) Nov 10, 2025
Q2 2025 Jun 30, 2025 ($21.49M) Aug 13, 2025
Q3 2025 Mar 31, 2025 ($18.18M) Nov 10, 2025
Q2 2025 Mar 31, 2025 ($18.18M) Aug 13, 2025
Q1 2025 Mar 31, 2025 ($18.18M) May 12, 2025
Q3 2025 Sep 30, 2024 ($15.12M) Nov 10, 2025
Q3 2025 Jun 30, 2024 ($11.70M) Nov 10, 2025
Q2 2025 Jun 30, 2024 ($11.70M) Aug 13, 2025
Q1 2025 Mar 31, 2024 ($12.28M) May 12, 2025
Q3 2025 Mar 31, 2024 ($12.28M) Nov 10, 2025
Q2 2025 Mar 31, 2024 ($12.28M) Aug 13, 2025
Q3 2024 Sep 30, 2023 ($10.36M) Nov 12, 2024
Q2 2024 Jun 30, 2023 ($11.11M) Aug 13, 2024
Q3 2024 Jun 30, 2023 ($11.11M) Nov 12, 2024
Q1 2024 Mar 31, 2023 ($371.0K) May 15, 2024
Q2 2024 Mar 31, 2023 ($371.0K) Aug 13, 2024
Q3 2024 Mar 31, 2023 ($371.0K) Nov 12, 2024
Q3 2023 Sep 30, 2022 ($4.07M) Nov 14, 2023
Q1 2023 Sep 30, 2022 ($4.07M) Nov 14, 2022

Operating Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($27.86M) Nov 10, 2025
Q2 2025 Jun 30, 2025 ($24.04M) Aug 13, 2025
Q1 2025 Mar 31, 2025 ($21.83M) May 12, 2025
Q3 2025 Sep 30, 2024 ($18.63M) Nov 10, 2025
Q2 2025 Jun 30, 2024 ($14.26M) Aug 13, 2025
Q1 2025 Mar 31, 2024 ($13.01M) May 12, 2025
Q3 2024 Sep 30, 2023 ($9.75M) Nov 12, 2024
Q2 2024 Jun 30, 2023 ($9.75M) Aug 13, 2024
Q1 2024 Mar 31, 2023 ($9.76M) May 15, 2024
Q3 2023 Sep 30, 2022 ($4.21M) Nov 14, 2023
Q1 2023 Sep 30, 2022 ($4.21M) Nov 14, 2022
Q2 2023 Jun 30, 2022 ($2.11M) Aug 11, 2023
Q3 2022 Mar 31, 2022 ($1.38M) May 13, 2022
Q1 2023 Mar 31, 2022 ($1.38M) May 15, 2023
Q2 2022 Dec 31, 2021 ($1.64M) Feb 9, 2022
Q1 2023 Sep 30, 2021 ($2.27M) Nov 14, 2022
Q3 2022 Mar 31, 2021 ($766.0K) May 13, 2022
Q2 2022 Dec 31, 2020 ($873.0K) Feb 9, 2022
Q1 2022 Sep 30, 2020 ($714.0K) Nov 10, 2021
Q3 2021 Mar 31, 2020 ($548.0K) May 14, 2021